Benzinga
Benzinga
Benzinga
miércoles, septiembre 30

Aldeyra Therapeutics Inc

ALDXNASDAQ
Trade with Public
Trade with Public
$1.30
-0.02-1.52%
Últ. Act.: Sep 30, 11:44 AM
PRO
¿Por qué se mueve?:Aldeyra Therapeutics shares are trading higher after the company announced ...
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Aldeyra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aldeyra Therapeutics (ALDX).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+457.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2026HC Wainwright & Co.Matthew CaufieldMaintainedNeutral$2
Sep 29, 2026BTIGThomas ShraderMaintainedBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved